ADMET studies perform a vital role in the drug discovery process. Early stage In-Silico models can predict the viability of a new novel drug before anyone steps into a lab. The In-Vitro and In-Vivo models allow the testing of new molecules to discover how tell they cope in a physiological environment and save Pharma companies millions by stoping the development of drugs destined to fail. As more data is generated by the lab studies, more data becomes available for the computational scientists and so out predictive abilities improve.
This conference will address the barriers that are currently faced by the PK/PD community and also how recent discoveries have improved the understanding of the mechanisms involved in ADME-Tox. It will also address the new technologies and techniques being developed to overcome the classic physiological barriers to drug bioavailability.
Attendees will hear presentations from senior experts in the field on the current issues as well as case studies from recent drug development programmes.
Key Topics to be addressed:
Unifying In-Silico, In-Vivo and In-Vitro results to generate the clearest predictions for novel molecules.
Optimisation of predictive studies
Drug transporters and their effect on our understanding of drug-drug interations and toxicity
The unique challanges faced in producing biologic drugs with high bioavailability
Developing reliable models of potential efflux
Hear expert addresses from:
Hugues Dolgos, Head of Global DMPK, Merck-Serono Dietmar Weitz, Lab Head / ADME in vitro Systems, Sanofi-Aventis Carl Petersson, Principal Scientist Medicinal Chemistry, AstraZeneca Andreas Reichel, Head of Research PK, Bayer Florence Namour, Senior DMPK Manager, Galapagos Kiyoyuki Omoto, Computational Scientist, Pfizer Laurent Salphati, Senior Scientist, Genentech Luca Settimo, Computational Chemist, Vertex Mikael Persson, Exploratory Toxicologist, Lundbeck Richard Weaver, Managing Director, XenoGesis Sid Bhoopathy, Chief Operating Officer, Absorption Systems Hinnerk Boriss, CEO, Sovicell Evita van de Steeg, Researcher, TNO Quality of Life Alexander Alex, Independent Consultant, Alexander Alex Consultancy
